Citation tools
"A phase II, open‐label study to assess safety and clinical utility of 68Ga‐THP‐PSMA PET/CT in patients with high‐risk primary prostate cancer or biochemical recurrence after radical treatment." Journal of Nuclear Medicine
61.supplement 1
(2020):
1259.
Web. 05 May. 2025.